Foghorn Therapeutics (FHTX) Financials: History & Chart

Foghorn Therapeutics Inc.(FHTX)

Biotechnology · Watertown, MA

$2.01+0.01 (+0.33%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

Watertown, MA

106 employees

foghorntx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Adrian H. Gottschalk

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	36.74M	16.07M	3.27M	9.25M	8.15M	7.56M	5.95M	2.86M	7.81M
Cost of Goods Sold	21.04M	0.00	238K	802K	20.00M	900K	0.00	0.00	0.00
Gross Profit	15.70M	16.07M	3.03M	8.45M	-11.85M	6.66M	5.95M	2.86M	7.81M
Gross Profit Margin	42.7%	100.0%	92.7%	91.3%	-145.3%	88.1%	100.0%	100.0%	100.0%
Total Operating Expenses	84.17M	24.88M	24.60M	28.04M	6.65M	27.75M	28.86M	26.86M	31.66M
Research & Development	79.73M	18.52M	18.26M	22.95M	20.00M	20.89M	21.63M	20.51M	24.69M
Selling, General & Administrative	26.38M	6.35M	6.58M	6.80M	6.65M	6.86M	7.24M	6.35M	6.97M
Operating Income (EBIT)	-68.47M	-8.80M	-21.57M	-19.60M	-18.50M	-21.10M	-22.91M	-24.00M	-23.85M
Operating Margin	-186.4%	-54.8%	-660.3%	-211.9%	-226.9%	-279.2%	-385.0%	-840.5%	-305.5%
Income Before Tax (EBT)	-64.58M	-7.19M	-19.88M	-21.66M	-15.85M	-17.94M	-18.83M	-19.50M	-19.12M
Interest Income	7.09M	1.61M	1.74M	1.71M	2.03M	2.31M	2.69M	3.10M	3.50M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	3.90M	1.61M	1.70M	-2.07M	2.65M	3.16M	4.08M	4.50M	4.73M
Net Income	-64.58M	-7.19M	-19.88M	-21.66M	-15.85M	-17.94M	-18.83M	-19.50M	-19.12M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-175.8%	-44.7%	-608.4%	-234.3%	-194.4%	-237.3%	-316.4%	-682.9%	-244.9%
EBITDA	-66.38M	-8.61M	-21.34M	-18.79M	-17.65M	-20.20M	-22.09M	-23.24M	-23.12M
EBITDA Margin	-180.7%	-53.5%	-653.0%	-203.2%	-216.5%	-267.3%	-371.1%	-813.9%	-296.1%
Depreciation & Amortization	2.09M	200K	238K	802K	852K	900K	827K	761K	733K
EPS Basic	-0.99	-0.10	-0.29	-0.35	-0.25	-0.28	-0.30	-0.31	-0.31
EPS Diluted	-0.99	-0.10	-0.29	-0.35	-0.25	-0.28	-0.30	-0.31	-0.31
Weighted Average Basic Shares	70.63M	70.63M	69.54M	62.98M	63.03M	62.98M	62.85M	62.60M	62.60M
Weighted Average Diluted Shares	70.63M	70.63M	69.54M	62.98M	63.03M	62.98M	62.85M	62.60M	62.60M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	30.91M	22.60M	34.16M	19.23M	1.32M	430K	0.00	0.00
Cost of Goods Sold	3.33M	0.00	0.00	0.00	0.00	57.72M	1.79M	379K
Gross Profit	27.58M	22.60M	34.16M	19.23M	1.32M	-57.28M	-1.79M	-379K
Gross Profit Margin	89.2%	100.0%	100.0%	100.0%	100.0%	-13322.1%	N/A	N/A
Total Operating Expenses	109.68M	125.28M	142.06M	136.37M	102.05M	11.25M	49.29M	26.05M
Research & Development	85.47M	94.53M	109.69M	105.62M	80.33M	57.72M	44.36M	21.23M
Selling, General & Administrative	27.55M	28.36M	32.37M	30.75M	21.73M	11.25M	4.93M	4.82M
Operating Income (EBIT)	-82.11M	-102.68M	-107.91M	-117.14M	-100.73M	-68.53M	-51.08M	-26.05M
Operating Margin	-265.6%	-454.3%	-315.9%	-609.2%	-7637.1%	-15937.4%	N/A	N/A
Income Before Tax (EBT)	-74.28M	-86.62M	-94.20M	-108.88M	-101.32M	-68.80M	-51.13M	-26.34M
Interest Income	8.74M	11.90M	10.88M	5.67M	59K	1.00M	495K	113K
Interest Expense	N/A	N/A	N/A	N/A	1.91M	979K	540K	371K
Other Income/Expense	7.82M	16.06M	13.71M	8.26M	-586K	-269K	-44K	-288K
Net Income	-74.28M	-86.62M	-98.43M	-108.88M	-101.32M	-68.80M	-51.13M	-26.34M
Income Tax Expense	0.00	0.00	4.23M	0.00	0.00	0.00	0.00	83K
Net Profit Margin	-240.3%	-383.2%	-288.2%	-566.3%	-7681.6%	-16000.0%	N/A	N/A
EBITDA	-78.78M	-99.56M	-104.45M	-113.82M	-97.51M	-67.20M	-49.29M	-25.67M
EBITDA Margin	-254.9%	-440.5%	-305.8%	-591.9%	-7392.5%	-15628.8%	N/A	N/A
Depreciation & Amortization	3.33M	3.12M	3.45M	3.32M	3.23M	1.33M	1.79M	379K
EPS Basic	-1.18	-1.58	-2.34	-2.62	-2.78	-1.90	-1.40	-1.34
EPS Diluted	-1.18	-1.58	-2.34	-2.62	-2.78	-1.90	-1.40	-1.34
Weighted Average Basic Shares	62.98M	54.90M	41.97M	41.59M	37.17M	36.79M	36.82M	19.63M
Weighted Average Diluted Shares	62.98M	54.90M	41.97M	41.59M	37.17M	36.79M	36.82M	19.63M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.